Thought starter
Let's assume you are a doctor asked to carry out an HIV test on a healthy European without any specific risk factors. You choose the best test available, which is 99.9% accurate. Unfortunately, the result is positive. Bad news for your patient? Not yet:
The prevalence of HIV-infection, i.e. proportion of infected people in the general population, in Europe, is about 1:10,000 inhabitants. This means, if testing 10,000 people you will pick up one real-positive but your best available test will show 10 false-positives. A positive result will thus only be correct in one out of 11 cases, i.e. the probability that your patient is really HIV-infected is about 9 %. A similar reasoning can be found in Gigerenzer et al. (1998) pointing out the need to communicate carefully any diagnosis to these patients.
What does this teach us as toxicologists? Our problem is in most cases, that we do not even know how accurate our test methods are (certainly less then 99.9 %), and have no indication of the prevalence, i.e. the proportion of toxic chemicals, for a given health effect in specific populations of chemicals.
This thought prompted us to elaborate, what diagnostic medicine can teach toxicology in handling the uncertainty of setting the diagnosis of a substance exerting a given toxic effect in our test methods.
The accuracy of the diagnosis -translation to toxicology
Setting a diagnosis in clinics is an art, which involves three aspects: the patient, the physician and the diagnostic measures (Haynes et al., 1996; Haynes et al., 2002) .
Difficulties in setting a diagnosis arise from incompatibilities and limitations of each component. When identifying a toxic hazard of a chemical, similar to the role of the physician, expertise of the assessor has to overcome the many limitations of our insight into the nature of the phenomena. In both cases a number of problems have to be considered (Table 1) .
It is impossible to judge the relative contribution of these factors. The conclusion is simple: Our tools to assign a toxic health effect are imperfect. This is well accepted in the field of clinical diagnostics (Boyko et al., 1988; Sackett et al., 1991; Hunink et al., 2001; Knottnerus et al., 2002; ) . However, in toxicology, we are not used to estimate and incorporate the uncertainty but we base the conclusion (i.e. labelling/classification as well as use or not-use of the substance for certain purposes) on this imperfect assessment.
Noteworthy, this review omits any discussion of the link of the relationship of a toxicity test to any adverse human health effect. The analysis is based only on the interplay of test quality and prevalence for a given test. This is principally applicable to any test, be it diagnostic in humans, in animals or in vitro.
The quality of our 'diagnostic' tools
The field of carcinogenicity, namely the rodent bioassay's 50 % positive rate triggered a detailed discussion of its restrictions and limitations regarding the predictive capacity for humans (Ames and Gold, 1990; Gold et al., 1998) . However, few toxicity tests have been studied with this scrutiny. The area of validation of alternative methods has pioneered the assessment of the quality of methods employed in toxicology (Balls et al., 1990; Balls et al., 1995) . The crucial achievement here was the concept of relevance, i.e. assessing not only the reliability/reproducibility, but also the predictive capacity of a method. This implies, however, to have a point of reference (usually termed 'reference standard'). In clinical diagnostics this reference is often included in systematic studies (Walter et al., 1999; Knottnerus and Muris, 2003) and new assessment tools have even been developed for study evaluation (Whiting et al., 2003) . In toxicology this optimal way of direct comparison most often is not applied due to cost or animal welfare considerations. If at all, a retrospective analysis in comparison to the reference (e.g. from databases) is carried out (Fentem et al., 1998) . In both disciplines, this reference standard is usually but not necessarily another test. In toxicology a consensus of experts on a list of substances' toxicological properties or classification could substitute here. In clinical diagnostics, sometimes similarly the reference standard to assess the performance of a diagnostic measure is established by consensus of an independent expert panel using patients' diagnosis established by clinical criteria (Weller and Mann, 1997; Knottnerus and Muris, 2003) .
It is of utmost importance to understand that validation assesses the reliability and relevance of methods. Figure 1 illustrates the validation process and which type of information constitutes the validity of a test method. Since often, the primary test result is not expressed identical to the reference test, a prediction model is required to translate one into the other (Worth and Balls, 2001) . For example, results of the test method might be continuous but must be classified into positive/negative or negative/mild/moderate/severe employing thresholds. In case of alternatives to animal experiments, the prediction model would translate from the in vitro result, e.g.
an IC 50 value, to an in vivo endpoint, e.g. LD 50 .
The quality and the adjustment of the prediction model is a key determinant of the predictive capacity of a test. In clinical diagnostics, designs and the sample sizes often allow threshold determination from the study data themselves (Sackett and Haynes, 2002) . In contrast, the prediction model in toxicology is normally developed before the validation study using a training set of substances (Bruner, 1996) . The quality and properties of this set pre-determines the quality of results and applicability of the test method. Similarly, the selection of patients to establish a diagnostic method determines its quality for its intended use, the so-called patient spectrum (Irwig et al., 2002) . If the selection is not representative or somehow flawed, e.g. only including severe cases, the relevance of the test will be impaired or restricted. Alike, it is instrumental that validation studies in toxicology include a sufficient number of weak toxicants. Optimally, although often a dichotomous, i.e. positive vs. negative, test outcome is chosen the selection should representatively cover the whole range of toxic potency. This allows a better test assessment by expressing probabilities, e.g. of being positive or negative, for each chemical: A highly toxic compound will be classified as such more likely as a moderate toxic compound. Another difference in prediction model development/threshold definition in clinical diagnostics is that the sample sizes are usually substantially larger. This eases biometrical assessment, but several advantages of setting a diagnosis of toxicity compared to clinical medicine can compensate here:
• Testing of substances can be synchronised
• Testing can be repeated
• Positive and negative controls are readily available
• Replicates and related substance testing is feasible
• The number of toxic health effects is limited 7
The impact of prevalence
As demonstrated in our thought starter, the prevalence of a disease is a key determinant of the practical value of a diagnostic measure (Buck and Gart, 1966; Linnet, 1988; Grimes and Schulz, 2002) . If you are looking for something rare, even the best test will produce too many false-positives to rely on the result. It is therefore crucial to use descriptors of test relevance, which take the prevalence into account.
In most simple cases (two outcomes of the test as well as for your reference standard), which will be mainly considered here for reasons of simplicity, this means to describe the relevance by the PPV (positive predictive value) and NPV (negative predictive value) instead of sensitivity, i.e. the probability of a correct negative result, and specificity, i.e. is the probability of a correct positive result. It would be challenging but also demanding to expand this concept of including prevalence information into multiple-class outcomes, as we have recently demonstrated for the case of skin irritation (Hoffmann et al., 2005) . The predictive values estimate the proportion of correct positives/negatives test outcomes in all positives/negatives and are thus an indication for the reliability of a positive/negative test result. However, in toxicology we often forget that our panel of test compounds is not reflecting the real world, but was designed to produce efficiently reliable estimates for sensitivity and specificity. For example, we choose 20 negatives and 20 positives not caring what the toxic effect is. Thus, the predictive values based on the artificial study prevalence are only telling us the predictive capacity of the test if the same distribution of positives and negatives is found in the real world. This is usually not the case. Unfortunately, for most toxicities we have no idea about their actual prevalence for example in chemicals of general use. Not only are we lacking complete information on basic toxic properties for a large number of high production 8 volume chemicals on the market (Allanou et al., 1999; EPA, 1998) , but even for the existing datasets no such analysis is available. Therefore, efforts should be spent in order to retrieve reliable estimates of those prevalences for the most relevant areas of toxicology.
Taking the example of skin irritation, this problem was recently approached (Hoffmann et al., 2005) . Although in this work also a detailed distribution of skin irritating potential was presented and analysed, we restrict ourselves here to the prevalence analysis of the dichotomous outcome, i.e. irritant vs. non-irritant. In the New Chemicals Database of the European Chemical Bureau, including 3121 chemicals mainly notified in the last 15 years, the prevalence of skin irritating substances (according to EU-regulation) assessed by an animal experiment was 7.9 %. The applicability domain with this prevalence would be the population of newly developed chemicals, while its use for other domains would have to be discussed.
Since the database contains only results from one test in one laboratory for each chemical, the predictive capacity of the in vivo experiment could only be modeled for the outcome of a repetition of the same experiment. This resulted in a specificity of 99.7 %, i.e. three out of 1000 non irritating chemicals would be classified false positive, and sensitivity of 94.1 %, i.e. 59 out of 1000 irritating chemicals would be classified false negative, and thus in a NPV of 99.5 %, i.e. only one out of 200 chemicals classified negative would in fact be an irritant, and a PPV of 96.8 %, i.e. out of 1000 chemicals classified as irritating 32 would be not irritating. It is evident, that modeling further aspects of variability, e.g. the within-and between-laboratory reproducibility, would decrease the predictive capacity estimates resulting in the respective decrease of the predictive values. For some combinations, the effect of prevalences and test accuracy, i.e. assuming that sensitivity equals specificity, on the predictive values is illustrated ( Table 2 ). The most important consequence of these considerations is that for rare toxic events we can rely on the negative, not on the positive test results.
As the negative predictive value is always close to 100 %, this shows that the idea to control negative test results in a second test, e.g. confirm negative in vitro results in vivo as suggested in the field of skin corrosion and irritation (OECD, 2002) , makes no sense at all for rare toxicities. Since the events are rare anyway, in most cases both test will be done, although the negative predictive value is high already. On the contrary, the positive ones have to be challenged, i.e. in regulatory toxicology avoiding over-classification of and unnecessary restrictions for substances. In this context, we are well aware of the most crucial safety aspect of false-negative
classifications, but the calculation shows that a second test can hardly improve the NPV, which is impaired by the false-negatives, of the first test. For example, for skin irritation even a test with only 70 % accuracy will identify negatives correctly in more than 96 % of the cases.
Consequences of inaccurate tests for prevalence determinations
An important question often overlooked is: How reliable are prevalences of rare diseases/toxicities, if assessed with our imperfect tools? If we agree that an in vivo experiment is not 100% accurate, many false-positives will populate our databases in case of rare toxicities. This means, that rare toxicities are rarer than we believe.
For illustration, we present some combinations of prevalence determined by a test with a given accuracy (Table 3) . For example, applying a 90 % accurate and finding a prevalence of 20 %, means that the true prevalence is only 12.5 %, i.e. only 5 out of 8 positive test substances are truly positive. Similarly, if we assume that the rabbit skin irritation test is 95 % accurate, more than half of the selected skin irritants (prevalence 7.9 %) would be false-positives.
An obvious consequence is that the usefulness of databases for selecting the proper reference standard data is limited. If we assume that the rabbit skin irritation test is 95 % accurate, more than 50 % of the selected skin irritants (prevalence 7.88 %) would be false-positives. As long as confirmatory testing in vivo is not carried out, it might be favorable to rely on the fewer, but more extensively studied substances from the scientific literature.
The use of confirmatory tests
It is common practice to apply a second test to confirm or challenge the results of a first test. When retesting positives, the specificity of the test procedure can be improved, when retesting negatives, the sensitivity of the test procedure can be improved. As we have seen above, this makes sense for relatively low prevalences only for positives, the NPV being almost optimal anyway. However, sensitivity and specificity of a test are interdependent: By defining for example the threshold value for a classification as positive or negative, one can be increased on cost of the other, usually demonstrated with receiver operation curves (ROC) as illustrated in Figure 2 (McNeil et al., 1975; van der Schouw et al., 1995) . This offers the opportunity to render tests extremely sensitive accepting impaired specificity, a situation typical for screening tests.
A commonly applied and simple strategy in clinics as well as in toxicology is the combination of a screening test with a subsequently performed confirmatory test.
With an oversensitive test a population is screened in order to detect as many positives as possible. Inevitably, this approach produces a lot of false-positive results in the first step. In a second step, all positively screened patients/substances are tested with a confirmatory test, which should be able to discriminate positives from negatives. The advantage of this strategy is often a reduction of costs, as screening tests with their lower overall predictive capacity are often substantially cheaper than their associated confirmatory tests. Nevertheless, the usefulness of this approach again strongly depends on the prevalence of the health effect (Buck and Gart, 1966) and the tests' dependence (Marshall, 1989) . If the prevalence is low, a screening test will result only in minor increase of the number of positives due to false-positives. By this the overall testing costs are strongly decreased, but the positive predictive value does not change tremendously, when compared to the PPV of the confirmatory test: For example let us assume a prevalence of 1%, an extremely sensitive screening assay with a sensitivity of 100%, but a specificity of only 50% and a good confirmatory assay with an accuracy of 95%. Testing 10000 substances, of which according to the assumed prevalence 100 are positive, the screen reduces the number of substances subjected to the confirmation test by 4950, i.e. all classified negatives. Applying now the confirmatory test reduces the overall NPV from 100 % to 99.95 %, i.e. 9652 of 9657 negatives are true negative, but results only in a PPV of 27.7 % (Table 4) Table 2) . This means, for rare health effects a sufficient specificity of the screening has to be maintained. Even close-to perfect confirmatory tests cannot compensate. In the given example, improved screening test specificity 80 % would result in a PPV of 49.0 % and a value of 90 % in a PPV of 65.7 % (Table 4) .
A solution to further increase PPV is the application of a series of complementary tests in a sequence. This solution bares the problem of loss in cost reduction and of the evaluation of the dependencies between tests as complementary screens might be difficult to find. Furthermore the efficacy of combining tests for rare health effects is limited even under optimal conditions, i.e. assuming test independency (Table 5) .
When combining a screening and a confirmatory test, the screening test balancing sensitivity and specificity has to be carefully designed and adjusted as falsenegative results in this step impair patients' health or consumers' safety. A more detailed insight into the prevalence is needed here to estimate consequences. One has also to consider the strength of a response and not only the dichotomized classification: It makes an enormous difference whether a large proportion of actual results is borderline to a given threshold or whether the negatives and positives are clearly distinct (Brenner and Gefeller, 1997; Bruner et al., 2002) . Especially in case of low prevalences, an extremely skewed distribution towards the negative end of the scale can be expected.
Prevalence in distinct chemical classes
So far we have handled the chemicals from the chemical universe only as a single entity. But they are related to other chemicals, e.g. by chemical structure, physiochemical properties or mechanism of action. If information of a related chemical is available, there is an increased probability that the considered chemical behaves toxicologically similar. This can be compared to the clinical situation where the integration of family anamnesis might change the probability of a diagnosis dramatically. Considering for example mutagenicity, in contrast of being a relatively rare toxic effect among all chemicals, it is more common for the chemical group of nitrosamines. Making use of this kind of a-priori information, structural alerts or read-across approaches should help to assign chemicals to families with high or low prevalence of health effects. This is by no means new but reflects practices of priority setting by (Q)SAR and similar computational approaches or simply experience of the risk assessor. What we, however, desperately need are measures of how close two substances are related. As long as these are missing, groups of chemicals should be considered mainly as classes with different prevalences and thus different certainty of test results allowing applying tests with different sensitivities and specificities. This calls for test strategies, which take into account general prevalence, chemical classes with their individual prevalences and the use of proper tests with suitable predictive capacities.
Conclusions
Toxicological test were reviewed as diagnostic tools to assess the toxicological properties of substances. Taking this point of view parallels between diagnostic medicine and toxicology can be found, where evidence-based medicine methodology should be explored and possibly adopted. To properly assess toxicological tests, their reliability and relevance need to be explored, a process, in which the reference standard is of crucial importance. If no appropriate reference standard exists, expert consensus can be a valid alternative. Nevertheless, reference standards will always be imperfect. Accounting for this imperfectness is crucial for a complete test evaluation. Here, the extent to which imperfect reference data might populate databases was demonstrated, especially with false-positives for low prevalence cases.
14 Furthermore, a systematic assessment of prevalences of toxic health effects in the chemical universe as well as in defined classes of chemicals is required. Only when combined with prevalence considerations, the 'diagnostic' value of a test can be estimated. For example, in low prevalence situations negative predictive values are almost optimal which challenges the approach of confirming negative results. In addition, we highlighted that the use of confirmatory tests strongly depends on prevalence and test accuracy. Additional information on substances, including chemicophysical properties, chemical structure or classes, might affect the prevalence. Therefore, for toxicological hazard identification and testing strategies integration of prevalence information is crucial. In this process, lessons can be learned from medical diagnosis setting and especially from the evidence-based evaluation of diagnostic measures as a step towards evidence-based toxicology. The interdependence of sensitivity and specificity of a test by moving the classification threshold can best be visualized by ROC graphs. The steeper the curve ascends, the better the test, i.e. combining high sensitivity with high specificity. Assuming a given test accuracy resulting from equal sensitivity and specificity, the consequences of different prevalences for the predictive values are calculated. n.d. = not defined, because for a given test accuracy, e.g. 90 %, the determined prevalence cannot be smaller than 100 % -accuracy, e.g. 100 % -90 % = 10 %.
The table presents the real underlying prevalences, when rare prevalences are determined with imperfect tests assuming accuracy = sensitivity = specificity. These calculations show the impact of the accuracy (assuming sensitivity = specificity) of a confirmatory test on the overall PPV when combined with a screening test with 100 % sensitivity, but varying specificity. 
24

